Results 101 to 110 of about 7,079 (166)

Mean global field power is reduced in infantile epileptic spasms syndrome after response to vigabatrin

Frontiers in Neurology
PurposeInfantile epileptic spasms syndrome (IESS) is associated with abnormal neuronal networks during a critical period of synaptogenesis and brain plasticity. Hypsarrhythmia is a visual EEG biomarker used to diagnose IESS, assess response to treatment,
Arjun Nair, Joycelyne Ewusie, Rowan Pentz, Robyn Whitney, Kevin Jones   +4 more
doaj   +1 more source

Epileptic–Dyskinetic Encephalopathy Associated with a PPP3CA Variant: Expansion of the Phenotypic Spectrum

Movement Disorders Clinical Practice, EarlyView.
Bruno Antunes Contrucci, Ursula Thomé, Larissa Aparecida Batista, Ana Laura Volpi Martins Lorenzoni, Carla Andrea Cardoso Tanuri Caldas, Americo Ceiki Sakamoto, Israel Gomy, Lisandra Mesquita Batista, Marcela Lopes de Almeida, Ana Paula Andrade Hamad, Guillermo Andrey Ariza Traslaviña   +10 more
wiley   +1 more source

Vigabatrin and Visual Loss

, 1998
Vigabatrin is an anti-epileptic agent which inhibits the enzyme responsible for the catabolism of the inhibitory neurotransmitter gamma-aminobutyric (GABA)
David H. Zackon, MD; A. Guberman; L Racette; S. K. Gupta
core  

Vigabatrin Monotherapy for Infantile Spasms

, 1995
The successful management of 21 children with infantile spasms and hypsarrhythmia using vigabatrin monotherapy is reported from the Alder Hey Children’s Hospital, Liverpool ...
J Gordon Millichap
core   +1 more source

Vigabatrin Associated Retinal Pathology

, 2002
A prospective study of 29 children treated with vigabatrin (VGB) as add on therapy for epilepsy included ophthalmic examination before and at 6-month intervals for 6.5 years, at Sultan Qaboos University Hospital, Sultanate of ...
J Gordon Millichap
core   +1 more source

GRIN1‐related epilepsy in a neonate with response to memantine and vigabatrin

Annals of the Child Neurology Society
Objective A newborn with GRIN1‐related early infantile developmental and epileptic encephalopathy (DEE) with striking pharmacoresistance is described with emphasis on potential therapy with memantine and vigabatrin.
Isabella Eiler, Hope M. Reecher, Katherine Carlton, Erwin Cabacungan, Susan Cohen, Samuel Adams, Jenna Jozwik, Avantika Singh   +7 more
doaj   +1 more source

Introduction and Lessons from Vigabatrin (video)

, 2017
Vigabatrin was introduced as an anti-seizure medication in the United Kingdom in 1989 and was extensively used until 1997 when concerns for peripheral visual field defects emerged.
Rod Foroozan
core  

Pharmacokinetics of Loading Dose Vigabatrin Administered via Enteral Tube in Participants With Post-Anoxic Status Epilepticus. [PDF]

Pharmacotherapy
Maranchick NF, Busl KM, Pop R, Miranda CG, Comparan HDM, Frota LM, Hirsch LJ, Eisenschenk S, Peloquin CA, Maciel CB.   +9 more
europepmc   +1 more source

Vigabatrin-related MRI changes and tapering strategy in hemispherotomy for infantile spasms: illustrative case. [PDF]

J Neurosurg Case Lessons
Houari L, Tang-Wai R, Hartnett S, Hernandez AW, Parikh N, Jallo G, Rodriguez LF, Akbari SHA, Smyth MD.   +8 more
europepmc   +1 more source

Everolimus initiated in the neonatal period for refractory seizures associated with tuberous sclerosis complex: long-term clinical outcome. [PDF]

Epilepsy Behav Rep
Suh YA, Kim SW, Choi S, Park MS, Lee JH, In Jeong S, Yu R, Sohn YB.   +7 more
europepmc   +1 more source